To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-dose E2/progestogen add-back therapy.
Source: fertstert.org
Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study
Published in Embryology and Reproductive Medicine
More from Embryology and Reproductive MedicineMore posts in Embryology and Reproductive Medicine »
- Life after Stillbirth
- The possible impact of COVID 19 on fertility and ART
- Human embryonic stem cell–derived blastocyst-like spheroids resemble human trophectoderm during early implantation process
- What support is available for you in hospital if you lose your baby
- Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis
Be First to Comment